SCHEMBL7528635

SCHEMBL7528635

CCCNc1cc(-c2ccccc2)ccc1OC

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.65
MAPT P10636 3/20 0.65
HPGD P15428 3/20 0.65
ALDH1A1 P00352 2/20 0.65
KMT2A Q03164 2/20 0.63
LMNA P02545 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
GAA P10253 1/20 0.62
ACLY P53396 8/20 0.48
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
GBA1 P04062 1/20 0.45
HDAC1 Q13547 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
LTB4R Q15722 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12230785 0.87 KDM4E (0.68) KDM4EMAPTHPGDALDH1A1KMT2A
SCHEMBL22000063 0.81 MAPT (0.81) KDM4EMAPTHPGDALDH1A1KMT2A
SCHEMBL13726348 0.79 MAPT (1.00) KDM4EMAPTHPGDALDH1A1KMT2A
SCHEMBL2261298 0.78 KDM4E (0.60) KDM4EMAPTHPGDALDH1A1KMT2A
SCHEMBL1644001 0.78 CHRM2 (0.64) MAPTHPGDALDH1A1L3MBTL1GAA
SCHEMBL5663443 0.77 KMT2A (0.51) KDM4EMAPTHPGDALDH1A1KMT2A
SCHEMBL7531918 0.77 MAPT (0.59) KDM4EMAPTALDH1A1KMT2ALMNA
SCHEMBL4459254 0.77 KDM4E (0.59) KDM4EMAPTHPGDALDH1A1KMT2A
SCHEMBL7529112 0.76 PTGS2 (0.44) KDM4EMAPTHPGDALDH1A1KMT2A
SCHEMBL7529150 0.76 KMT2A (0.55) MAPTALDH1A1KMT2ALMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020137740-A1 Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them FONTAINE EVELYNE (FR) 2002-09-26 US disclosed
EP-0934290-B1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI SYNTHELABO (FR) 2002-04-17 EP disclosed
US-6344470-B1 Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same SANOFI-SYNTHELABO (FR) 2002-02-05 US disclosed
EP-0934290-A1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1999-08-11 EP disclosed
WO-1998015543-A1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1998-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137740-A1 Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them CRHR1, ADRA1D, ADRB1 KDM4E 2054/4885MAPT 1420/4885HPGD 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.